Inhibitec Anticuerpos S.L.
Inhibitec Anticuerpos SL was founded in 2019 (Santander, Spain), with the goal of introducing a new treatment for patients with psoriasis and Psoriatic Arthritis (PsA) based in the blockade of BAMBI (BMP and Activin Membrane-Bound Inhibitor).While psoriasis is a CD4 T cell-mediated autoimmune disease of the skin that affects 2% of the global population (160 million patients), PsA is a more debilitating condition developed in 30% of the cases with lesions affecting not only the skin but the joints. Our mission revolves around addressing a pressing issue within the PsA community: the discouragingly inadequate response of roughly 40% of patients to recently developed biologics, leaving them far from achieving the essential minimum threshold of efficacy, as defined by the ACR20 standard.
Utilizing our groundbreaking monoclonal antibody (mAb), B101.37, to target BAMBI introduces a pioneer and disruptive approach to clinical improvement which relays on its unique dual mechanism of action. This first-in-class antibody directly reduces pro-inflammatory Th17 cells while enhancing the number and functionality of Treg cells.
The technology described for B101.37 mAb has been protected by an International Patent filed in November 2015 and owned by the Spanish National Research Council (CSIC) and University of Cantabria (UC). This patent extension to the EU (PCT/ES2016/070852) and USA (US2022332809) has been approved in 2022. Inhibitec has an exclusive license for the commercialization an exploitation of the above-mentioned BAMBI patent (patent officer Hoffman Eitle S.L.U).